Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

The Doomsday Clock moves to a historic 89 seconds, citing AI and bioengineering risks as major threats to humanity. Explore ...

and it is typically found mixed with tick material rather than in a purified form, complicating experimental procedures. However, once CRISPR-Cas9 editing is established, we will be able to ...

In late 2023, it secured US Food and Drug Administration (FDA) approval for its CRISPR-based therapy Casgevy (exa-cel ... a challenge that Orna’s lipid nanoparticle technology could address. Tick here ...

She understands the ethical implications of CRISPR and is determined to ensure ... Once you find what makes you tick, you can dive in headfirst. This might be helping out in your neighborhood ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...

Then Crispr came along—the elegant enzymatic apparatus that allows delivery of DNA scissors to a specific target in the genome. In December 2023, the FDA approved the first Crispr-based therapy ...

Bring up germline editing, and most scientists cringe. The idea behind the notorious CRISPR-baby scandal, editing reproductive cells or embryos tinkers with DNA far beyond just the patient—any changes ...